CLINICAL_TRIALS
trial_result
· 2020-04-01
Clinical Trial Update: Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies [Phase 1]
Summary
Phase 1 dose-escalation study of MLN0128 in participants with advanced solid malignancies has completed and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2020-04-01